Lantern Deferred Long Term Liab vs Total Assets Analysis

LTRN Stock

USD 3.07 0.06 1.92%

Lantern Pharma financial indicator trend analysis is infinitely more than just investigating Lantern Pharma recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lantern Pharma is a good investment. Please check the relationship between Lantern Pharma Deferred Long Term Liab and its Total Assets accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lantern Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.

Deferred Long Term Liab vs Total Assets

Deferred Long Term Liab vs Total Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lantern Pharma Deferred Long Term Liab account and Total Assets. At this time, the significance of the direction appears to have pay attention.

The correlation between Lantern Pharma's Deferred Long Term Liab and Total Assets is -0.9. Overlapping area represents the amount of variation of Deferred Long Term Liab that can explain the historical movement of Total Assets in the same time period over historical financial statements of Lantern Pharma, assuming nothing else is changed. The correlation between historical values of Lantern Pharma's Deferred Long Term Liab and Total Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Deferred Long Term Liab of Lantern Pharma are associated (or correlated) with its Total Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Assets has no effect on the direction of Deferred Long Term Liab i.e., Lantern Pharma's Deferred Long Term Liab and Total Assets go up and down completely randomly.

Correlation Coefficient

-0.9

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Deferred Long Term Liab

Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.

Total Assets

Total assets refers to the total amount of Lantern Pharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Lantern Pharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Most indicators from Lantern Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lantern Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lantern Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.As of the 27th of November 2024, Selling General Administrative is likely to drop to about 4.2 M. Issuance Of Capital Stock is expected to grow at the current pace this year

Lantern Pharma fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Capital Surpluse	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Common Stock	Property Plant Equipment	Other Assets	Other Current Assets
Total Assets		0.76	0.92	1.0	0.98	0.79	-0.99	-0.79	0.62	0.99	0.8	0.03	1.0	-0.89	0.95	0.92	0.97	0.93	1.0	1.0	-0.88	1.0	-0.89	0.86	0.39	0.83
Other Current Liab	0.76		0.94	0.75	0.85	0.81	-0.65	-0.86	0.75	0.65	0.46	-0.19	0.76	-0.63	0.91	0.84	0.86	0.94	0.75	0.76	-0.64	0.75	-0.63	0.53	0.03	0.78
Total Current Liabilities	0.92	0.94		0.92	0.95	0.82	-0.85	-0.88	0.72	0.85	0.59	-0.11	0.92	-0.8	0.99	0.92	0.97	1.0	0.92	0.92	-0.8	0.92	-0.8	0.68	0.14	0.9
Total Stockholder Equity	1.0	0.75	0.92		0.98	0.79	-0.99	-0.78	0.61	0.99	0.8	0.03	1.0	-0.89	0.95	0.91	0.97	0.92	1.0	1.0	-0.88	1.0	-0.89	0.87	0.39	0.82
Net Tangible Assets	0.98	0.85	0.95	0.98		0.84	-0.94	-0.84	0.69	0.94	0.76	0.02	0.98	-0.89	0.97	0.93	0.99	0.96	0.98	0.98	-0.88	0.98	-0.89	0.81	0.31	0.83
Property Plant And Equipment Net	0.79	0.81	0.82	0.79	0.84		-0.73	-0.93	0.93	0.74	0.67	0.03	0.79	-0.8	0.87	0.94	0.85	0.83	0.79	0.79	-0.78	0.79	-0.8	0.69	0.14	0.67
Net Debt	-0.99	-0.65	-0.85	-0.99	-0.94	-0.73		0.71	-0.53	-1.0	-0.82	-0.07	-0.99	0.89	-0.89	-0.86	-0.93	-0.86	-0.99	-0.99	0.87	-0.99	0.89	-0.88	-0.45	-0.77
Retained Earnings	-0.79	-0.86	-0.88	-0.78	-0.84	-0.93	0.71		-0.96	-0.72	-0.45	-0.08	-0.78	0.85	-0.89	-0.96	-0.88	-0.89	-0.78	-0.79	0.83	-0.78	0.84	-0.51	0.15	-0.86
Accounts Payable	0.62	0.75	0.72	0.61	0.69	0.93	-0.53	-0.96		0.54	0.38	0.17	0.61	-0.74	0.75	0.88	0.73	0.73	0.61	0.62	-0.71	0.61	-0.74	0.39	-0.23	0.68
Cash	0.99	0.65	0.85	0.99	0.94	0.74	-1.0	-0.72	0.54		0.82	0.07	0.99	-0.89	0.9	0.87	0.93	0.86	0.99	0.99	-0.88	0.99	-0.89	0.88	0.45	0.78
Non Current Assets Total	0.8	0.46	0.59	0.8	0.76	0.67	-0.82	-0.45	0.38	0.82		0.13	0.8	-0.61	0.69	0.65	0.7	0.6	0.8	0.79	-0.57	0.8	-0.61	0.98	0.79	0.33
Non Currrent Assets Other	0.03	-0.19	-0.11	0.03	0.02	0.03	-0.07	-0.08	0.17	0.07	0.13		0.03	-0.18	-0.04	0.06	0.04	-0.09	0.03	0.03	-0.01	0.03	-0.19	0.0	-0.1	0.03
Cash And Short Term Investments	1.0	0.76	0.92	1.0	0.98	0.79	-0.99	-0.78	0.61	0.99	0.8	0.03		-0.89	0.95	0.91	0.97	0.93	1.0	1.0	-0.88	1.0	-0.89	0.87	0.39	0.82
Common Stock Total Equity	-0.89	-0.63	-0.8	-0.89	-0.89	-0.8	0.89	0.85	-0.74	-0.89	-0.61	-0.18	-0.89		-0.83	-0.91	-0.91	-0.82	-0.89	-0.89	0.98	-0.89	1.0	-0.66	-0.08	-0.83
Common Stock Shares Outstanding	0.95	0.91	0.99	0.95	0.97	0.87	-0.89	-0.89	0.75	0.9	0.69	-0.04	0.95	-0.83		0.95	0.98	0.99	0.95	0.95	-0.82	0.95	-0.83	0.76	0.23	0.87
Capital Surpluse	0.92	0.84	0.92	0.91	0.93	0.94	-0.86	-0.96	0.88	0.87	0.65	0.06	0.91	-0.91	0.95		0.96	0.93	0.91	0.92	-0.9	0.91	-0.91	0.7	0.09	0.86
Other Stockholder Equity	0.97	0.86	0.97	0.97	0.99	0.85	-0.93	-0.88	0.73	0.93	0.7	0.04	0.97	-0.91	0.98	0.96		0.98	0.97	0.97	-0.89	0.97	-0.91	0.76	0.22	0.89
Total Liab	0.93	0.94	1.0	0.92	0.96	0.83	-0.86	-0.89	0.73	0.86	0.6	-0.09	0.93	-0.82	0.99	0.93	0.98		0.92	0.93	-0.82	0.93	-0.82	0.69	0.14	0.9
Net Invested Capital	1.0	0.75	0.92	1.0	0.98	0.79	-0.99	-0.78	0.61	0.99	0.8	0.03	1.0	-0.89	0.95	0.91	0.97	0.92		1.0	-0.88	1.0	-0.89	0.87	0.39	0.82
Total Current Assets	1.0	0.76	0.92	1.0	0.98	0.79	-0.99	-0.79	0.62	0.99	0.79	0.03	1.0	-0.89	0.95	0.92	0.97	0.93	1.0		-0.88	1.0	-0.89	0.86	0.38	0.83
Capital Stock	-0.88	-0.64	-0.8	-0.88	-0.88	-0.78	0.87	0.83	-0.71	-0.88	-0.57	-0.01	-0.88	0.98	-0.82	-0.9	-0.89	-0.82	-0.88	-0.88		-0.88	0.98	-0.65	-0.09	-0.82
Net Working Capital	1.0	0.75	0.92	1.0	0.98	0.79	-0.99	-0.78	0.61	0.99	0.8	0.03	1.0	-0.89	0.95	0.91	0.97	0.93	1.0	1.0	-0.88		-0.89	0.86	0.39	0.82
Common Stock	-0.89	-0.63	-0.8	-0.89	-0.89	-0.8	0.89	0.84	-0.74	-0.89	-0.61	-0.19	-0.89	1.0	-0.83	-0.91	-0.91	-0.82	-0.89	-0.89	0.98	-0.89		-0.66	-0.09	-0.83
Property Plant Equipment	0.86	0.53	0.68	0.87	0.81	0.69	-0.88	-0.51	0.39	0.88	0.98	0.0	0.87	-0.66	0.76	0.7	0.76	0.69	0.87	0.86	-0.65	0.86	-0.66		0.77	0.43
Other Assets	0.39	0.03	0.14	0.39	0.31	0.14	-0.45	0.15	-0.23	0.45	0.79	-0.1	0.39	-0.08	0.23	0.09	0.22	0.14	0.39	0.38	-0.09	0.39	-0.09	0.77		-0.17
Other Current Assets	0.83	0.78	0.9	0.82	0.83	0.67	-0.77	-0.86	0.68	0.78	0.33	0.03	0.82	-0.83	0.87	0.86	0.89	0.9	0.82	0.83	-0.82	0.82	-0.83	0.43	-0.17

Click cells to compare fundamentals

Lantern Pharma Account Relationship Matchups

Lantern Pharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.4M	20.4M	74.0M	58.8M	43.6M	36.4M
Other Current Liab	489.3K	120K	1.5M	1.8M	2.5M	1.3M
Total Current Liabilities	489.3K	552.3K	2.3M	2.8M	2.7M	1.7M
Total Stockholder Equity	943.3K	19.7M	71.6M	56.0M	40.9M	34.6M
Net Tangible Assets	943.0K	19.7M	71.6M	56.0M	64.4M	32.6M
Property Plant And Equipment Net	8.8K	21.5K	216.2K	95.7K	280.4K	294.4K
Net Debt	(1.2M)	(19.1M)	(51.3M)	(37.1M)	(21.7M)	(22.8M)
Retained Earnings	(6.8M)	(12.7M)	(25.0M)	(39.3M)	(55.2M)	(52.5M)
Accounts Payable	489.3K	432.3K	681.1K	932.4K	2.5M	2.6M
Cash	1.2M	19.2M	51.5M	37.2M	21.9M	24.1M
Non Current Assets Total	199.8K	122.7K	1.2M	113.6K	306.3K	363.2K
Cash And Short Term Investments	1.2M	19.2M	70.7M	55.2M	41.3M	34.5M
Common Stock Shares Outstanding	6.3M	6.2M	10.9M	10.9M	10.8M	9.4M
Liabilities And Stockholders Equity	1.4M	20.4M	74.0M	58.8M	43.6M	36.4M
Other Stockholder Equity	7.7M	32.4M	96.7M	95.7M	96.3M	61.0M
Total Liab	489.3K	660.8K	2.4M	2.8M	2.7M	1.8M
Net Invested Capital	929.3K	19.8M	71.6M	56.0M	40.9M	34.7M
Total Current Assets	1.2M	20.2M	72.7M	58.7M	43.3M	36.1M
Capital Stock	25.4K	622.0	1.1K	1.1K	1.1K	1.0K
Net Working Capital	743.5K	19.7M	70.4M	55.9M	40.7M	34.3M
Property Plant Equipment	8.8K	21.5K	216.2K	48.0K	55.2K	65.8K

Pair Trading with Lantern Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lantern Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lantern Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with Lantern Stock

0.7	ME	23Andme Holding	Pair Corr
0.68	VALN	Valneva SE ADR	Pair Corr

Moving against Lantern Stock

0.48	KZR	Kezar Life Sciences	Pair Corr
0.4	NXGLW	NexGel Warrant	Pair Corr
0.38	MLYS	Mineralys Therapeutics,	Pair Corr
0.33	MDGL	Madrigal Pharmaceuticals	Pair Corr

The ability to find closely correlated positions to Lantern Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lantern Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lantern Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lantern Pharma to buy it.

The correlation of Lantern Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lantern Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lantern Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Lantern Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Lantern Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lantern Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lantern Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lantern Pharma Stock:

How To Invest In Lantern

Details

Is Lantern Stock a good investment?

Details

What is Lantern Pharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lantern Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.

You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantern Pharma. If investors know Lantern will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantern Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.78)

Return On Assets

(0.28)

Return On Equity

(0.45)

The market value of Lantern Pharma is measured differently than its book value, which is the value of Lantern that is recorded on the company's balance sheet. Investors also form their own opinion of Lantern Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lantern Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantern Pharma's market value can be influenced by many factors that don't directly affect Lantern Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Lantern Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantern Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantern Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lantern Deferred Long Term Liab vs Total Assets Analysis

Deferred Long Term Liab vs Total Assets

Deferred Long Term Liab vs Total Assets Correlation Analysis

Correlation Coefficient

Deferred Long Term Liab

Total Assets

Lantern Pharma fundamental ratios Correlations

Lantern Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Lantern Pharma fundamental ratios Accounts

Pair Trading with Lantern Pharma

Moving together with Lantern Stock

Moving against Lantern Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities

Cash	- 1.0	Net Debt
Net Working Capital	- 0.99	Net Debt
Total Current Assets	- 0.99	Net Debt
Net Invested Capital	- 0.99	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Net Debt	- 0.99	Total Stockholder Equity